Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Indiana Healthcare Today.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on August 26, 2025
PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
GlobeNewswire
·
August 26, 2025
SALT LAKE CITY, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the …
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
GlobeNewswire
·
August 26, 2025
LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update …
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
GlobeNewswire
·
August 26, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead …
Adagene to Participate in Two Investor Conferences in September
GlobeNewswire
·
August 26, 2025
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy …
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
GlobeNewswire
·
August 26, 2025
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad - …
Proxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue Discovery
GlobeNewswire
·
August 26, 2025
VIENNA and LAUSANNE, Switzerland, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Proxygen, a global leader in the discovery and development of molecular glue degraders, today announced a strategic research collaboration with EPFL (the Swiss Federal Institute of …
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
GlobeNewswire
·
August 26, 2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor …
InnovAge to Announce Fourth Quarter and Fiscal 2025 Financial Results and Host Conference Call Tuesday, September 9, 2025
GlobeNewswire
·
August 26, 2025
DENVER, Aug. 26, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All- …
Global Healthcare Dispensing Systems Market to Reach USD 6.27 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 26, 2025
Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The global healthcare dispensing systems market, valued at US$4.36 billion in 2024, stood at US$4.61 billion in 2025 and is projected to advance at a resilient CAGR of 6.3% from 2025 to 2030, culminating …
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: …
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside …
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
GlobeNewswire
·
August 26, 2025
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
Prime Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will …
Compass Therapeutics to Participate in Upcoming September Investor Events
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today …
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
GlobeNewswire
·
August 26, 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
GlobeNewswire
·
August 26, 2025
MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly Psi-GAD), a psilocybin- …
Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress
GlobeNewswire
·
August 26, 2025
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration represents a potential paradigm shift from frequent in-office …
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
GlobeNewswire
·
August 26, 2025
WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a …
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
GlobeNewswire
·
August 26, 2025
Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for central …
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
GlobeNewswire
·
August 26, 2025
TORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a …